Literature DB >> 33466884

SARS-CoV-2 in Mexico: Beyond Detection Methods, Scope and Limitations.

Cynthia Martinez-Liu1, Natalia Martínez-Acuña1, Daniel Arellanos-Soto1, Kame Galan-Huerta1, Sonia Lozano-Sepulveda1, María Del Carmen Martínez-Guzmán2, Ana Maria Rivas-Estilla1.   

Abstract

The new coronavirus that was first identified in December 2019 in Wuhan China, now called SARS-CoV-2, which causes the disease called COVID-19, has spread from China to the entire world in a few months. Due to its contagious potential (R0: 5.7) and because there is still no effective treatment to stop the infection, and a vaccine for prevention it is not yet available to the general population, COVID-19 is currently considered a global health problem. The need to implement sensitive methods for the identification of individuals with COVID-19 has led to the development of different molecular and immunological tests. The importance of a timely and accurate diagnosis is essential to determine the course of the pandemic. The interpretation of the results obtained by each test as well as the factors that affect these results have not been fully described. In this review, we describe and analyze the different SARS-CoV-2 detection methods that have been performed in Mexico and are available worldwide, outlining their strengths and weaknesses. Further, a broader perspective of the correct use and interpretation of the results obtained with these diagnostic tools is proposed to improve the containment strategy and identify the true impact of the pandemic.

Entities:  

Keywords:  CLIA; COVID-19; ELISA; IgG; IgM; SARS-CoV-2; antibodies; diagnostic test; immune host response; immunoassay; lateral flow assay; rapid test; viral detection

Year:  2021        PMID: 33466884      PMCID: PMC7830507          DOI: 10.3390/diagnostics11010124

Source DB:  PubMed          Journal:  Diagnostics (Basel)        ISSN: 2075-4418


  50 in total

Review 1.  Diagnostic performance of COVID-19 serology assays.

Authors:  Z Zainol Rashid; S N Othman; M N Abdul Samat; U K Ali; K K Wong
Journal:  Malays J Pathol       Date:  2020-04       Impact factor: 0.656

Review 2.  Clinical, molecular, and epidemiological characterization of the SARS-CoV-2 virus and the Coronavirus Disease 2019 (COVID-19), a comprehensive literature review.

Authors:  Esteban Ortiz-Prado; Katherine Simbaña-Rivera; Lenin Gómez-Barreno; Mario Rubio-Neira; Linda P Guaman; Nikolaos C Kyriakidis; Claire Muslin; Ana María Gómez Jaramillo; Carlos Barba-Ostria; Doménica Cevallos-Robalino; Hugo Sanches-SanMiguel; Luis Unigarro; Rasa Zalakeviciute; Naomi Gadian; Andrés López-Cortés
Journal:  Diagn Microbiol Infect Dis       Date:  2020-05-30       Impact factor: 2.803

3.  Comparison of diagnostic accuracies of rapid serological tests and ELISA to molecular diagnostics in patients with suspected coronavirus disease 2019 presenting to the hospital.

Authors:  D S Y Ong; S J de Man; F A Lindeboom; J G M Koeleman
Journal:  Clin Microbiol Infect       Date:  2020-06-02       Impact factor: 8.067

4.  iSCAN: An RT-LAMP-coupled CRISPR-Cas12 module for rapid, sensitive detection of SARS-CoV-2.

Authors:  Zahir Ali; Rashid Aman; Ahmed Mahas; Gundra Sivakrishna Rao; Muhammad Tehseen; Tin Marsic; Rahul Salunke; Amit K Subudhi; Sharif M Hala; Samir M Hamdan; Arnab Pain; Fadwa S Alofi; Afrah Alsomali; Anwar M Hashem; Asim Khogeer; Naif A M Almontashiri; Malak Abedalthagafi; Norhan Hassan; Magdy M Mahfouz
Journal:  Virus Res       Date:  2020-08-18       Impact factor: 3.303

5.  Serology characteristics of SARS-CoV-2 infection after exposure and post-symptom onset.

Authors:  Bin Lou; Ting-Dong Li; Shu-Fa Zheng; Ying-Ying Su; Zhi-Yong Li; Wei Liu; Fei Yu; Sheng-Xiang Ge; Qian-Da Zou; Quan Yuan; Sha Lin; Cong-Ming Hong; Xiang-Yang Yao; Xue-Jie Zhang; Ding-Hui Wu; Guo-Liang Zhou; Wang-Heng Hou; Ting-Ting Li; Ya-Li Zhang; Shi-Yin Zhang; Jian Fan; Jun Zhang; Ning-Shao Xia; Yu Chen
Journal:  Eur Respir J       Date:  2020-08-27       Impact factor: 16.671

6.  Detection of SARS-CoV-2 antibodies using commercial assays and seroconversion patterns in hospitalized patients.

Authors:  E Tuaillon; K Bolloré; A Pisoni; S Debiesse; C Renault; S Marie; S Groc; C Niels; N Pansu; A M Dupuy; D Morquin; V Foulongne; A Bourdin; V Le Moing; P Van de Perre
Journal:  J Infect       Date:  2020-06-03       Impact factor: 6.072

7.  Clinical characteristics of 24 asymptomatic infections with COVID-19 screened among close contacts in Nanjing, China.

Authors:  Zhiliang Hu; Ci Song; Chuanjun Xu; Guangfu Jin; Yaling Chen; Xin Xu; Hongxia Ma; Wei Chen; Yuan Lin; Yishan Zheng; Jianming Wang; Zhibin Hu; Yongxiang Yi; Hongbing Shen
Journal:  Sci China Life Sci       Date:  2020-03-04       Impact factor: 10.372

Review 8.  Fragile Endothelium and Brain Dysregulated Neurochemical Activity in COVID-19.

Authors:  Abdulrahman Alharthy; Fahad Faqihi; Ziad A Memish; Dimitrios Karakitsos
Journal:  ACS Chem Neurosci       Date:  2020-07-27       Impact factor: 4.418

9.  ACE2 Expression in Pancreas May Cause Pancreatic Damage After SARS-CoV-2 Infection.

Authors:  Furong Liu; Xin Long; Bixiang Zhang; Wanguang Zhang; Xiaoping Chen; Zhanguo Zhang
Journal:  Clin Gastroenterol Hepatol       Date:  2020-04-22       Impact factor: 11.382

10.  A Recurrent Mutation at Position 26340 of SARS-CoV-2 Is Associated with Failure of the E Gene Quantitative Reverse Transcription-PCR Utilized in a Commercial Dual-Target Diagnostic Assay.

Authors:  Maria Artesi; Sébastien Bontems; Marie-Pierre Hayette; Vincent Bours; Keith Durkin; Paul Göbbels; Marc Franckh; Piet Maes; Raphaël Boreux; Cécile Meex; Pierrette Melin
Journal:  J Clin Microbiol       Date:  2020-09-22       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.